Literature DB >> 2724417

Identification of a region within the human immunodeficiency virus type 1 long terminal repeat that is essential for transactivation by the hepatitis B virus gene X.

J S Twu1, C A Rosen, W A Haseltine, W S Robinson.   

Abstract

Hepatitis B virus (HBV) X-gene product activates transcription of the chloramphenicol acetyltransferase (CAT) gene under control of the human immunodeficiency virus type 1 (HIV-1) long terminal repeat (LTR). To identify a cis-acting regulatory sequence within the HIV-1 LTR which is responsive to the HBV X-gene trans-activating function, we examined the effects of HBV X-gene expression in cells with a series of LTR/CAT deletion mutants. A region of the HIV-1 LTR containing the previously identified kappa B-like enhancer element was found to be responsive to HBV X-gene activation, and this effect was independent of, and additive with, the effect of the HIV-1 tat-III protein on CAT expression. Since kappa B-like enhancer sequences are known to regulate transcription of a variety of viruses and cellular genes, our results suggest that the X gene could activate such a gene during HBV infection and replication.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2724417      PMCID: PMC250800     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  25 in total

1.  Transcriptional trans-activating function of hepatitis B virus.

Authors:  J S Twu; R H Schloemer
Journal:  J Virol       Date:  1987-11       Impact factor: 5.103

2.  Multiple cis- and trans-acting elements mediate the transcriptional response to phorbol esters.

Authors:  R Chiu; M Imagawa; R J Imbra; J R Bockoven; M Karin
Journal:  Nature       Date:  1987 Oct 15-21       Impact factor: 49.962

3.  Positive and negative regulation of transcription in vitro: enhancer-binding protein AP-2 is inhibited by SV40 T antigen.

Authors:  P J Mitchell; C Wang; R Tjian
Journal:  Cell       Date:  1987-09-11       Impact factor: 41.582

4.  A common positive trans-acting factor binds to enhancer sequences in the promoters of mouse H-2 and beta 2-microglobulin genes.

Authors:  A Israël; A Kimura; M Kieran; O Yano; J Kanellopoulos; O Le Bail; P Kourilsky
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

5.  Binding of a nuclear factor to a regulatory sequence in the promoter of the mouse H-2Kb class I major histocompatibility gene.

Authors:  A S Baldwin; P A Sharp
Journal:  Mol Cell Biol       Date:  1987-01       Impact factor: 4.272

6.  Hepatitis B virus X gene can transactivate heterologous viral sequences.

Authors:  J S Twu; W S Robinson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

7.  Hepatitis B virus DNA sequences in lymphoid cells from patients with AIDS and AIDS-related complex.

Authors:  F Laure; D Zagury; A G Saimot; R C Gallo; B H Hahn; C Brechot
Journal:  Science       Date:  1985-08-09       Impact factor: 47.728

8.  Tumor promoter, TPA, enhances replication of HTLV-III/LAV.

Authors:  S Harada; Y Koyanagi; H Nakashima; N Kobayashi; N Yamamoto
Journal:  Virology       Date:  1986-10-30       Impact factor: 3.616

9.  Extrachromosomal sequences of hepatitis B virus DNA in peripheral blood mononuclear cells of acquired immune deficiency syndrome patients.

Authors:  C A Noonan; B Yoffe; P W Mansell; J L Melnick; F B Hollinger
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

10.  Trans-activation of the human immunodeficiency virus long terminal repeat sequence by DNA viruses.

Authors:  H E Gendelman; W Phelps; L Feigenbaum; J M Ostrove; A Adachi; P M Howley; G Khoury; H S Ginsberg; M A Martin
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

View more
  22 in total

1.  Mutational analysis of enhancer domains responsive to trans-activation by the X gene of human hepatitis B virus.

Authors:  G Goodarzi; H Ohno; R Adams; A Darabi; A Tewari; M Watabe; K Watabe
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

2.  Detection of a hepatitis B virus variant with a truncated X gene and enhancer II.

Authors:  R Repp; C Keller; A Borkhardt; A Csecke; S Schaefer; W H Gerlich; F Lampert
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

3.  Mutual functional antagonism of the simian virus 40 T antigen and the hepatitis B virus trans activator.

Authors:  E Seto; T S Yen
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

4.  The X-gene of human hepatitis B virus transactivates the c-jun and alpha-fetoprotein genes.

Authors:  M X Zhou; M Watabe; K Watabe
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

5.  Hepatitis B virus X protein produced in Escherichia coli is biologically functional.

Authors:  S Jameel; A Siddiqui; H F Maguire; K V Rao
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

6.  Activation of the human immunodeficiency virus type 1 long terminal repeat by transforming mutants of human p53.

Authors:  M A Subler; D W Martin; S Deb
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

7.  Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria.

Authors:  John Idoko; Seema Meloni; Mohammed Muazu; Ladep Nimzing; Bitrus Badung; Claudia Hawkins; Jean-Louis Sankalé; Ernest Ekong; Robert Murphy; Phyllis Kanki; Chloe L Thio
Journal:  Clin Infect Dis       Date:  2009-10-15       Impact factor: 9.079

8.  Regulation of transcription from the hepatitis B virus major surface antigen promoter by the Sp1 transcription factor.

Authors:  A K Raney; H B Le; A McLachlan
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

9.  Human cytomegalovirus inhibits human immunodeficiency virus replication in cells productively infected by both viruses.

Authors:  V Koval; C Clark; M Vaishnav; S A Spector; D H Spector
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

Review 10.  Hepatitis B virus infection and primary hepatocellular carcinoma.

Authors:  M Feitelson
Journal:  Clin Microbiol Rev       Date:  1992-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.